C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/12 (2006.01) A61K 31/506 (2006.01) A61P 35/00 (2006.01) C07D 401/14 (2006.01) C07D 405/14 (2006.01) C07D 409/14 (2006.01)
Patent
CA 2697077
The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR.alpha., PDGFR.beta., CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF.beta., SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK20, BRK, Fms, KDR, c-raf or b-raf kinases.
L'invention concerne des composés de formule (I) et des compositions pharmaceutiques de ceux-ci, qui sont utiles en tant qu'inhibiteurs de protéine kinase, ainsi que des procédés d'utilisation de tels composés pour traiter, améliorer ou prévenir une affection associée à une activité de kinase anormale ou dérégulée. Dans certains modes de réalisation, l'invention propose des procédés d'utilisation de tels composés pour traiter, améliorer ou prévenir des maladies ou troubles qui impliquent une activation anormale des kinases c-kit, PDGFRa, PDGFRß, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFß, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2ß, BRK, Fms, KDR, c-raf ou b-raf.
Chianelli Donatella
Li Xiaolin
Liu Xiaodong
Loren Jon
Molteni Valentina
Fetherstonhaugh & Co.
Irm Llc
LandOfFree
2-heteroarylamino-pyrimidine derivatives as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1357271